JP2019534044A - 抗ｐｄ１および抗ｃｔｌａ４抗体 - Google Patents

抗ｐｄ１および抗ｃｔｌａ４抗体 Download PDF

Info

Publication number
JP2019534044A
JP2019534044A JP2019545717A JP2019545717A JP2019534044A JP 2019534044 A JP2019534044 A JP 2019534044A JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019545717 A JP2019545717 A JP 2019545717A JP 2019534044 A JP2019534044 A JP 2019534044A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
nos
hctla4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019545717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534044A5 (https=
Inventor
リュウ，チ
ジョンファ，フー
シー． ファンスロウ，ウィリアム
シー． ファンスロウ，ウィリアム
ヤン，ウェイ
Original Assignee
クイル ピュージェット サウンド バイオセラピューティクス コーポレーション
クイル ピュージェット サウンド バイオセラピューティクス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クイル ピュージェット サウンド バイオセラピューティクス コーポレーション, クイル ピュージェット サウンド バイオセラピューティクス コーポレーション filed Critical クイル ピュージェット サウンド バイオセラピューティクス コーポレーション
Publication of JP2019534044A publication Critical patent/JP2019534044A/ja
Publication of JP2019534044A5 publication Critical patent/JP2019534044A5/ja
Priority to JP2022087695A priority Critical patent/JP7455897B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019545717A 2016-11-08 2017-11-06 抗ｐｄ１および抗ｃｔｌａ４抗体 Pending JP2019534044A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022087695A JP7455897B2 (ja) 2016-11-08 2022-05-30 抗ｐｄ１および抗ｃｔｌａ４抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662419157P 2016-11-08 2016-11-08
US62/419,157 2016-11-08
PCT/US2017/060122 WO2018089293A2 (en) 2016-11-08 2017-11-06 Anti-pd1 and anti-ctla4 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022087695A Division JP7455897B2 (ja) 2016-11-08 2022-05-30 抗ｐｄ１および抗ｃｔｌａ４抗体

Publications (2)

Publication Number Publication Date
JP2019534044A true JP2019534044A (ja) 2019-11-28
JP2019534044A5 JP2019534044A5 (https=) 2021-02-12

Family

ID=60409406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019545717A Pending JP2019534044A (ja) 2016-11-08 2017-11-06 抗ｐｄ１および抗ｃｔｌａ４抗体
JP2022087695A Active JP7455897B2 (ja) 2016-11-08 2022-05-30 抗ｐｄ１および抗ｃｔｌａ４抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022087695A Active JP7455897B2 (ja) 2016-11-08 2022-05-30 抗ｐｄ１および抗ｃｔｌａ４抗体

Country Status (7)

Country Link
US (2) US11124570B2 (https=)
EP (1) EP3538137A2 (https=)
JP (2) JP2019534044A (https=)
CN (2) CN118480125A (https=)
AU (1) AU2017356860A1 (https=)
CA (1) CA3042249A1 (https=)
WO (1) WO2018089293A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017269115B2 (en) * 2016-05-26 2024-06-20 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
CA3042249A1 (en) 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies
JP7625521B2 (ja) * 2018-12-28 2025-02-03 トランスジーン ｍ２欠陥ポックスウイルス
US20220235144A1 (en) 2019-03-04 2022-07-28 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
EP4021579A1 (en) 2019-08-30 2022-07-06 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
US12473349B2 (en) * 2020-05-06 2025-11-18 Korea University Research And Business Foundation PD-1 variants having increased PD-L1 affinity
CN111875697B (zh) * 2020-08-03 2021-10-01 杭州皓阳生物技术有限公司 一种包含肽标签的融合蛋白
EP4294531A4 (en) * 2021-02-18 2025-07-16 Qilu Puget Sound Biotherapeutics Corp COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES
WO2023160517A1 (zh) * 2022-02-22 2023-08-31 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN119255817A (zh) * 2022-03-28 2025-01-03 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
CN118946366A (zh) * 2022-04-13 2024-11-12 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
US20250313643A1 (en) * 2022-06-07 2025-10-09 Unm Rainforest Innovations Humanized non-opioid composition and therapies for pain management
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2024002226A1 (zh) * 2022-06-30 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
TW202525861A (zh) * 2023-12-01 2025-07-01 大陸商齊魯製藥有限公司 穩定的混合抗體的藥物組合物
WO2025228542A1 (en) 2024-05-03 2025-11-06 Genmab B.V. Method for co-expression of a plurality of antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670075B2 (en) 1992-02-26 1996-07-04 Allergan, Inc. Use of platelet derived growth factor in ophthalmic wound healing
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK1141028T3 (da) * 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
IL148079A0 (en) * 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
RU2494107C2 (ru) * 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
EP2286220A2 (en) * 2008-05-29 2011-02-23 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the co-stimulatory pathway
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
CA2777226A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
EP2630160B1 (en) 2010-10-18 2016-11-09 MediaPharma S.r.l. Erbb3 binding antibody
IN2013MN01438A (https=) 2011-03-17 2015-06-12 Univ Ramot
CN202105787U (zh) 2011-06-03 2012-01-11 杨自强 糠粞分离机
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10118971B2 (en) 2013-03-13 2018-11-06 Ibentrus, Inc. Protein in which electrical interaction is introduced within hydrophobic interaction site and preparation method therefor
MY184154A (en) * 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
US10954301B2 (en) * 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
CA3042249A1 (en) 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anti-pd1 and anti-ctla4 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4

Also Published As

Publication number Publication date
JP2022119917A (ja) 2022-08-17
US20220135683A1 (en) 2022-05-05
JP7455897B2 (ja) 2024-03-26
WO2018089293A3 (en) 2019-01-24
US20190276542A1 (en) 2019-09-12
AU2017356860A1 (en) 2019-05-16
CN110312523A (zh) 2019-10-08
WO2018089293A2 (en) 2018-05-17
CN118480125A (zh) 2024-08-13
US12037397B2 (en) 2024-07-16
CN110312523B (zh) 2024-04-26
US11124570B2 (en) 2021-09-21
CA3042249A1 (en) 2018-05-17
EP3538137A2 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
JP7455897B2 (ja) 抗ｐｄ１および抗ｃｔｌａ４抗体
AU2015341884B2 (en) CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
AU2015299101B2 (en) Bispecific antibodies against CD3epsilon and BCMA
ES2984937T3 (es) Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
ES2774380T3 (es) Politerapia de inmunocitocinas de variante de IL-2 dirigida a tumor y anticuerpos frente a PD-L1 humano
WO2022256563A1 (en) Anti-ccr8 antibodies and uses thereof
AU2018348431B2 (en) Antibodies targeting CD137 and methods of use thereof
US20180194862A1 (en) Bispecific binding proteins
KR20200055052A (ko) 신규 항-cd3엡실론 항체
US20220235144A1 (en) Anti-sirp-alpha antibodies
KR20160010391A (ko) Cd20 및 cd95에 결합하는 재조합 이중특이성 항체
CN120731225A (zh) Il-2融合蛋白
WO2024155807A1 (en) Multispecific antibodies and uses thereof
WO2019018402A2 (en) ANTIGEN-BINDING REGIONS DIRECTED AGAINST FIBRONECTIN TYPE III DOMAINS AND METHODS OF USING THE SAME
JP2022545834A (ja) 抗ｃｄ２０抗体、抗ｃｄ３７抗体、およびこれらの混合物
JP7430137B2 (ja) 抗体および使用方法
Jang et al. Development of an antibody-like T-cell engager based on VH-VL heterodimer formation and its application in cancer therapy
EP4431525A1 (en) Il-2 fusion protein
EP4527851A1 (en) Bispecific antibodies binding ltbr and lrrc15
CN117858899A (zh) 抗ccr8抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220726